It was a year of ups and downs for the embryonic advanced air mobility industry as some companies made progress toward certification and operation, while for others the struggle to find funding in a difficult capital market took them to the edge—or beyond.
It was a year of ups and downs for the embryonic advanced air mobility industry as some companies made progress toward certification and operation, while for others the struggle to find funding in a difficult capital market took them to the edge—or beyond.